SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs) -- Ignore unavailable to you. Want to Upgrade?


To: allen menglin chen who wrote (1291)7/10/2000 3:10:22 AM
From: bob zagorin  Read Replies (1) | Respond to of 1972
 
i think they have a lock on this gene delivery platform - direct. all the genomic / protein based therapeutics, i think, will have to get around the delivery problems associated with virus. i think this buying opportunity has something to do with the interim CEO situation. meanwhile, here is update from 7/7

SG Cowen Securities
VICL Reiterated Buy, signs Aventis Pharma as licensee for Naked DNA, $1.5M booked in Q2